<?xml version="1.0" encoding="UTF-8"?>
<p>The literature has identified the complement system as an essential host mediator for both SARS-CoV- and MERS-CoV-induced disease and has suggested that complement activation controls the systemic pro-inflammatory response against the viral infection [
 <xref rid="B84-pharmaceuticals-13-00096" ref-type="bibr">84</xref>,
 <xref rid="B85-pharmaceuticals-13-00096" ref-type="bibr">85</xref>]. Accordingly, eculizumab is expected to stop immune-mediated death in patients infected with SARS-CoV-2. Currently, the drug is under clinical trials for its effectiveness in patients with confirmed COVID-19 infection who are in ICU due to ARDS (NCT04288713). 
</p>
